The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia.
Differential expression of molecules in chronic lymphocytic leukemia (CLL) may define prognostic markers and suitable targets for immunotherapy. Expression of the tumor-associated antigen (TAA) RHAMM (receptor for hyaluronic acid-mediated motility) as well as RHAMM splicing variants was assessed in series of 72 CLL patients. Quantitative reverse transcriptase PCR showed higher RHAMM expression in high-risk CLL patients, as well as in the advanced stages of the disease. CLL cases with a higher RHAMM expression showed a significantly shorter median treatment-free survival. Among patients with mutated immunoglobulin heavy chain genes, an analysis of RHAMM expression enabled to distinguish subgroup of patients with favorable prognosis. In lymph nodes, RHAMM staining correlated with a higher Ki-67 index and CD40L expression. Functionally, stimulation with CD40L enhanced RHAMM expression in CLL. We further characterized RHAMM-specific CD8(+) T cells in patients with CLL, as the expression of TAAs might influence the clinical outcome by the means of immune reactions. The cytotoxic potential of RHAMM-specific T cells was shown against target cells bearing RHAMM-derived epitope as well as against CLL cells expressing RHAMM. In conclusion, RHAMM expression appears to be of prognostic value, as well as may reflect the proliferative capacity of CLL cells, and might therefore represent interesting target for immunotherapy.
Giannopoulos
K
K
Department of Internal Medicine III, University of Ulm, Ulm, Germany. giannop@tlen.pl
Mertens
D
D
Bühler
A
A
Barth
T F E
TF
Idler
I
I
Möller
P
P
Kröber
A
A
Greiner
J
J
Chocholska
S
S
Dmoszyñska
A
A
Roliñski
J
J
Döhner
H
H
Stilgenbauer
S
S
Schmitt
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D023201:CD40 Ligand / Q000032:analysis / Q000494:pharmacology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000473:pathology; D002455:Cell Division; D003602:Cytotoxicity, Immunologic; D018450:Disease Progression; D018572:Disease-Free Survival; D016326:Extracellular Matrix Proteins / Q000032:analysis / Q000502:physiology*; D005260:Female; D006801:Humans; D018960:Hyaluronan Receptors / Q000032:analysis / Q000502:physiology*; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis / Q000502:physiology*; D011379:Prognosis; D020033:Protein Isoforms / Q000032:analysis / Q000502:physiology; D012326:RNA Splicing; D020133:Reverse Transcriptase Polymerase Chain Reaction
D016326:Extracellular Matrix Proteins; D018960:Hyaluronan Receptors; D007143:Immunoglobulin Heavy Chains; D009363:Neoplasm Proteins; D020033:Protein Isoforms; C098946:hyaluronan-mediated motility receptor; D023201:CD40 Ligand